HC Wainwright reaffirmed their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS – Free Report) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock.
Separately, Piper Sandler reiterated an “overweight” rating and issued a $7.00 price objective on shares of Alpha Tau Medical in a research report on Thursday, August 15th.
Get Our Latest Stock Analysis on Alpha Tau Medical
Alpha Tau Medical Stock Down 0.9 %
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. As a group, equities analysts forecast that Alpha Tau Medical will post -0.48 EPS for the current year.
Institutional Investors Weigh In On Alpha Tau Medical
A number of institutional investors have recently made changes to their positions in DRTS. Levin Capital Strategies L.P. boosted its position in shares of Alpha Tau Medical by 2.6% during the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after purchasing an additional 8,641 shares during the period. Caprock Group LLC purchased a new position in shares of Alpha Tau Medical during the second quarter worth $59,000. Aptus Capital Advisors LLC grew its stake in shares of Alpha Tau Medical by 83.7% in the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. raised its holdings in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares during the period. Finally, USAdvisors Wealth Management LLC acquired a new position in Alpha Tau Medical during the 1st quarter worth about $30,000. 2.65% of the stock is currently owned by institutional investors and hedge funds.
About Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Read More
- Five stocks we like better than Alpha Tau Medical
- Industrial Products Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the S&P/TSX Index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Trading Halts Explained
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.